An alternative form of melarsoprol in sleeping sickness.

摘要: Human African trypanosomiasis (HAT), or sleeping sickness, is a major threat to human health throughout sub-Saharan Africa. Almost always fatal if untreated inadequately treated, commonly used drug for treating late-stage HAT, and the only Trypanosoma brucei rhodesiense, intravenous melarsoprol, which kills 5% of patients receiving it. Melarsoprol cyclodextrin inclusion complexes have been tested in highly reliable mouse model HAT. These increase oral bioavailability melarsoprol making them effective orally both curative nontoxic doses that are equivalent those melarsoprol. It argued small clinical trial this HAT justified potentially improve outcome with rhodesiense disease.